AntonioJaimeSanchezMD

Gastroenterology • Iowa City, IA

Hepatology & Liver Transplantation

Director of Hepatology Clinical Professor, Internal Medicine, University of Iowa College of Medicine

Join to view full profile

Dr. Sanchez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sanchez's full profile

Already have an account?

Office
200 Hawkins Dr
Iowa City, IA 52242
Phone+1 319-356-2132

Fax+1 319-356-7918
Is this information wrong?

Summary

Dr. Antonio Sanchez is the Director of Hepatology at the University of Iowa Hospitals and Clinics. He received his medical degree from Universidad de Guayaquil n Ecuador, Internal Medicine training at the University of Illinois and fellowship training at the Mayo Clinic. He specializes in hepatology & liver transplantation. His clinical and research focus is in general hepatology, transplant hepatology, nutrition in liver disease, and medical education.

Education & Training

Mayo Clinic College of Medicine and Science (Jacksonville)Fellowship, Transplant Hepatology, 2006
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2002 - 2005
Universidad de Guayaquil, School of Medicine.Class of 2000

Certifications & Licensure

IA State Medical License 2006 - 2026
FL State Medical License 2005 - 2025
IL State Medical License 2002 - 2007
American Board of Internal Medicine Internal Medicine

Clinical Trials

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Start of enrollment: 2013 Jun 01
Completed
Phase 2
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Start of enrollment: 2014 Sep 18
Completed
Phase 2
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Start of enrollment: 2016 Jul 13
Completed
Phase 3
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24
Terminated
Phase 2
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Apr 05
Terminated
Phase 3
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Start of enrollment: 2017 Feb 13
Terminated
Phase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Jan 30
Terminated
Phase 3
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Start of enrollment: 2017 Apr 28
Completed
Phase 3
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2017 Dec 27
Completed
Phase 2
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH Start of enrollment: 2020 Jan 27
Terminated
Phase 2
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) Start of enrollment: 2020 Nov 11
Terminated
Phase 2
A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Start of enrollment: 2021 Apr 27
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.
Heidi S Ahmed, Nikitha Gangasani, Manju B Jayanna, Michelle T Long, Antonio Sanchez, Arvind R Murali> ;Journal of Clinical and Experimental Hepatology. 2022 Nov 12
5 citations
Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease
Heidi S. Ahmed, Natalie Pedersen, Manju Bengaluru Jayanna, Patrick Ten Eyck, Antonio J. Sanchez, Arvind R. Murali> ;Journal of General Internal Medicine. 2020 Mar 10
9 citations
Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.
Yolanda Rodriguez Villalvazo, Jennifer S. McDanel, Lauren A. Beste, Antonio J. Sanchez, Mary Vaughan-Sarrazin, David A. Katz> ;Health Services Research. 2020 Feb 1
28 citations
Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.
Elisabet Reyes-Irisarri, Antonio Sánchez, J.A. García-Merino, Guadalupe Mengod> ;Journal of Neuropathology and Experimental Neurology. 2007 Oct 1
2 citations
Nutrition in hepatic failure and liver transplantation.
Antonio J. Sanchez, Jaime Aranda-Michel> ;Revista De Gastroenterologia De Mexico. 2007 Oct 1
58 citations
Nutrition for the liver transplant patient.
Antonio J. Sanchez, Jaime Aranda-Michel> ;Liver Transplantation. 2006 Sep 1
18 citations
Liver disease and osteoporosis.
Antonio J. Sanchez, Jaime Aranda-Michel> ;Nutrition in Clinical Practice. 2006 Jun 1
Join now to see all

Journal Articles

Hyperammonemic encephalopathy: time course of MRI diffusion changes
Capizzano AA, Sanchez A, Moritani T, Yager J., Neurology, 2/21/2012
Isoniazid-associated pancreatitis
Sanchez AJ, Boken D, Infections in Medicine 21(12):622-623 · December 2004

Abstracts/Posters